Cost of Cancer Diagnosis Using Next-generation Sequencing Targeted Gene Panels in Routine Practice

Completed

• Conditions: Cancer

• Registration Number: NCT04656717
• Lead Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

Brief Summary

The aim of this study was to measure the total cost of performing next-generation sequencing (NGS) in clinical practice in France, in both germline and somatic cancer genetics.

The study was performed on 15 French representative cancer molecular genetics laboratories performing NGS panels' tests. The production cost was estimated using a micro-costing method with resources consumed collected in situ in each laboratory from a healthcare provider perspective. A top-down methodology for specific post-sequencing steps was used.

Additional non-specific costs were also included and costs were detailed per step of the process.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-03
• Primary Completion: 2015-11
• Study Completion: 2015-11
• Study First Submitted: 2019-05-26
• Status Verified: 2020-12
• Study First Submitted QC: 2020-12-04
• Last Update Submitted: 2020-12-04
• Study First Posted: 2020-12-07
• Last Update Posted: 2020-12-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

• French genetics laboratories performing somatic and germline clinical NGS tests.

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall production cost	through study completion, an average of 5 years	The study is performed on 15 French representative cancer molecular genetics laboratories performing NGS panels' tests. The production cost is estimated using a micro-costing method with resources consumed collected in situ in each laboratory from a healthcare provider perspective. A top-down methodology for specific post-sequencing steps is used.